EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
RS60759B1
(sr)
*
|
2013-02-26 |
2020-10-30 |
Memorial Sloan Kettering Cancer Center |
Sastavi i postupci za imunoterapiju
|
SG11201507688VA
(en)
*
|
2013-03-15 |
2015-10-29 |
Sloan Kettering Inst Cancer |
Compositions and methods for immunotherapy
|
JP5885885B2
(ja)
|
2013-03-29 |
2016-03-16 |
大日本住友製薬株式会社 |
Wt1抗原ペプチドコンジュゲートワクチン
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
JP7060324B2
(ja)
|
2013-12-20 |
2022-04-26 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ネオ抗原ワクチンによる併用療法
|
US11390921B2
(en)
|
2014-04-01 |
2022-07-19 |
Adaptive Biotechnologies Corporation |
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
|
MA39867A
(fr)
|
2014-04-23 |
2017-03-01 |
Juno Therapeutics Inc |
Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
|
EP3143134B1
(en)
|
2014-05-15 |
2020-10-28 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
SG11201700416TA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
DK3177640T3
(da)
|
2014-08-08 |
2020-08-10 |
Univ Leland Stanford Junior |
Pd-1-midler med høj affinitet og anvendelsesfremgangsmåder
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
BR112017005390A2
(pt)
*
|
2014-09-17 |
2017-12-12 |
Novartis Ag |
células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
|
US10507219B2
(en)
|
2014-10-20 |
2019-12-17 |
Juno Therapeutics, Inc. |
Methods and compositions for dosing in adoptive cell therapy
|
ES2897731T3
(es)
*
|
2014-10-27 |
2022-03-02 |
Hutchinson Fred Cancer Res |
Composiciones y métodos para reforzar la eficacia de la inmunoterapia celular adoptiva
|
US20170258835A1
(en)
*
|
2014-10-31 |
2017-09-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for modified t cells
|
PT3226897T
(pt)
|
2014-12-05 |
2021-04-13 |
Eureka Therapeutics Inc |
Anticorpos tendo como alvo o antigénio de maturação das células b e métodos de utilização
|
ES2966099T3
(es)
|
2014-12-05 |
2024-04-18 |
Memorial Sloan Kettering Cancer Center |
Receptores de antígeno quiméricos dirigidos al antígeno de maduración de células B y usos de los mismos
|
EP3227436A4
(en)
|
2014-12-05 |
2018-06-20 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
AU2015364245B2
(en)
*
|
2014-12-19 |
2020-04-02 |
Dana-Farber Cancer Institute, Inc. |
Chimeric antigen receptors and methods of use thereof
|
CN107249604A
(zh)
*
|
2014-12-31 |
2017-10-13 |
人类起源公司 |
使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
KR102605464B1
(ko)
|
2015-01-30 |
2023-11-22 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
일차 조혈 세포에서의 단백질 전달
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
EP3549612A1
(en)
*
|
2015-03-02 |
2019-10-09 |
Innovative Cellular Therapeutics Co., Ltd. |
Reducing immune tolerance induced by pd-l1
|
WO2016161415A2
(en)
|
2015-04-02 |
2016-10-06 |
Memorial Sloan Kettering Cancer Center |
Tnfrsf14/ hvem proteins and methods of use thereof
|
MX2017013247A
(es)
|
2015-04-15 |
2018-08-15 |
Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center |
Infusion arterial hepatica de linfocitos t car.
|
EP3288568A4
(en)
*
|
2015-04-30 |
2019-01-02 |
University of Southern California |
Secretory tnt car cell immunotherapy
|
CN114634943A
(zh)
|
2015-05-18 |
2022-06-17 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
TW202346325A
(zh)
|
2015-05-20 |
2023-12-01 |
美商博德研究所有限公司 |
共有之gata3相關之腫瘤特異性新抗原
|
JP6515182B2
(ja)
*
|
2015-05-20 |
2019-05-15 |
大日本住友製薬株式会社 |
Wt1抗原ペプチドおよび免疫調節剤の併用
|
EP3436575A1
(en)
|
2015-06-18 |
2019-02-06 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2016210129A1
(en)
*
|
2015-06-23 |
2016-12-29 |
Memorial Sloan-Kettering Cancer Center |
Novel pd-1 immune modulating agents
|
US10822419B2
(en)
|
2015-06-26 |
2020-11-03 |
University Of Southern California |
Masking chimeric antigen receptor T cells for tumor-specific activation
|
EP3328399B1
(en)
|
2015-07-31 |
2023-12-27 |
Regents of the University of Minnesota |
Modified cells and methods of therapy
|
CN105111314B
(zh)
*
|
2015-08-13 |
2019-01-08 |
成都百世博生物技术有限公司 |
一种新型融合蛋白、药物组合物及其制备方法和用途
|
EA201890790A1
(ru)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
WO2017059168A1
(en)
|
2015-10-01 |
2017-04-06 |
Heat Biologics, Inc. |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
CN106350533B
(zh)
*
|
2015-10-09 |
2020-07-17 |
上海宇研生物技术有限公司 |
Anti-PD-L1-CAR-T及其制备方法和应用
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
CN105331585A
(zh)
*
|
2015-11-13 |
2016-02-17 |
科济生物医药(上海)有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
US10533157B1
(en)
|
2015-12-03 |
2020-01-14 |
Nantbio, Inc. |
Recombinant NK cells expressing co-stimulatory molecules
|
KR20180089497A
(ko)
|
2015-12-04 |
2018-08-08 |
메모리얼 슬로안-케터링 캔서 센터 |
Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법
|
WO2017133175A1
(en)
*
|
2016-02-04 |
2017-08-10 |
Nanjing Legend Biotech Co., Ltd. |
Engineered mammalian cells for cancer therapy
|
RU2018128464A
(ru)
*
|
2016-02-25 |
2020-03-25 |
Селл Медика Свитзерленд Аг |
Связывающие элементы против pd-l1
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
EP3452082A1
(en)
|
2016-05-04 |
2019-03-13 |
Fred Hutchinson Cancer Research Center |
Cell-based neoantigen vaccines and uses thereof
|
CN105950561A
(zh)
*
|
2016-05-26 |
2016-09-21 |
江苏杰晟生物科技有限公司 |
一种靶向乳腺癌干细胞的双特异性嵌合抗原受体基因修饰的t淋巴细胞的制备方法及其产品
|
WO2017210689A1
(en)
|
2016-06-03 |
2017-12-07 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
US11390658B2
(en)
|
2016-06-06 |
2022-07-19 |
St. Jude Children's Research Hospital |
Anti-CD7 chimeric antigen receptor and method of use thereof
|
CN107523549A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达激活型抗体的car‑t细胞及其用途
|
CN107523545A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达抗体的杀伤性细胞及其用途
|
CN107523547A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达抑制性抗体的car‑t细胞及其用途
|
CN117903316A
(zh)
*
|
2016-07-29 |
2024-04-19 |
朱诺治疗学股份有限公司 |
抗独特型抗体及相关方法
|
AU2017301880C1
(en)
|
2016-07-29 |
2022-04-21 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
CN109715668A
(zh)
|
2016-08-02 |
2019-05-03 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重编程的组合物和方法
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
SG11201901950TA
(en)
|
2016-09-19 |
2019-04-29 |
Celgene Corp |
Methods of treating immune disorders using pd-1 binding proteins
|
JP2019529565A
(ja)
*
|
2016-09-28 |
2019-10-17 |
アトッサ・ジェネティックス・インコーポレイテッド |
養子細胞治療の方法
|
US11072660B2
(en)
|
2016-10-03 |
2021-07-27 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
PL3445787T3
(pl)
|
2016-10-07 |
2021-05-31 |
TCR2 Therapeutics Inc. |
Kompozycje i sposoby reprogramowania receptorów limfocytów t przy użyciu białek fuzyjnych
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
GB2605540B
(en)
|
2016-10-18 |
2022-12-21 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
CN107964549B
(zh)
*
|
2016-10-20 |
2020-12-08 |
上海恒润达生生物科技有限公司 |
靶向cd22的嵌合抗原受体及其用途
|
WO2018081784A1
(en)
*
|
2016-10-31 |
2018-05-03 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Artificial antigen presenting cells for expanding immune cells for immunotherapy
|
AU2017363278B2
(en)
|
2016-11-22 |
2022-10-27 |
National University Of Singapore |
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
KR20190098747A
(ko)
|
2016-12-05 |
2019-08-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료법을 위한 조작된 세포의 제조방법
|
IL267589B1
(en)
|
2016-12-23 |
2024-07-01 |
Macrogenics Inc |
ADAM9 binding molecules and methods of their use
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
CN108395478A
(zh)
*
|
2017-02-04 |
2018-08-14 |
上海恒润达生生物科技有限公司 |
靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
|
BR112019016657A2
(pt)
|
2017-02-12 |
2020-04-07 |
Neon Therapeutics Inc |
métodos baseados em hla e composições e usos destes
|
WO2018152033A1
(en)
*
|
2017-02-14 |
2018-08-23 |
Promab Biotechnologies, Inc. |
Cd47-car-t cells
|
CN108424461B
(zh)
*
|
2017-02-14 |
2023-03-31 |
亘喜生物科技(上海)有限公司 |
Cd47-car-t细胞
|
US11845803B2
(en)
|
2017-02-17 |
2023-12-19 |
Fred Hutchinson Cancer Center |
Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
|
AU2018224852A1
(en)
|
2017-02-27 |
2019-07-11 |
Shattuck Labs, Inc. |
VSIG8-based chimeric proteins
|
BR112019017713A2
(pt)
|
2017-02-27 |
2020-04-07 |
Shattuck Labs Inc |
proteínas quiméricas à base de csf1r
|
IL313003A
(en)
|
2017-02-27 |
2024-07-01 |
Shattuck Labs Inc |
Chimeric proteins based on TIGIT and LIGHT
|
US11896616B2
(en)
|
2017-03-27 |
2024-02-13 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
KR20240057444A
(ko)
|
2017-03-27 |
2024-05-02 |
내셔널 유니버시티 오브 싱가포르 |
절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
|
MX2019012398A
(es)
|
2017-04-18 |
2020-09-25 |
Broad Inst Inc |
Composiciones para detectar secreciones y metodos de uso.
|
AU2018254517A1
(en)
*
|
2017-04-19 |
2019-12-05 |
University Of Southern California |
Compositions and methods for treating cancer
|
AU2018258046A1
(en)
|
2017-04-26 |
2019-12-12 |
Eureka Therapeutics, Inc. |
Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
|
CN111406068A
(zh)
|
2017-05-16 |
2020-07-10 |
约翰霍普金斯大学 |
MANAbody及使用方法
|
CN108864286B
(zh)
*
|
2017-05-16 |
2023-08-29 |
上海恒润达生生物科技股份有限公司 |
靶向cd19的嵌合抗原受体及联合表达抗pd1抗体可变区的方法和及其用途
|
US10780119B2
(en)
|
2017-05-24 |
2020-09-22 |
Effector Therapeutics Inc. |
Methods and compositions for cellular immunotherapy
|
CN107245500B
(zh)
*
|
2017-05-27 |
2019-05-17 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
|
CN107164410B
(zh)
*
|
2017-05-27 |
2019-09-03 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用
|
CN107325185B
(zh)
*
|
2017-06-06 |
2019-09-20 |
上海优卡迪生物医药科技有限公司 |
基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体
|
CN107337736B
(zh)
*
|
2017-06-06 |
2019-07-26 |
上海优卡迪生物医药科技有限公司 |
Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
JP2020530307A
(ja)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス,インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
EP3652209A2
(en)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonist antibodies that bind human cd137 and uses thereof
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
CN107337737B
(zh)
*
|
2017-07-18 |
2020-02-07 |
深圳市免疫基因治疗研究院 |
一种嵌合抗原受体及其应用
|
CN107245106B
(zh)
*
|
2017-07-18 |
2020-06-12 |
深圳市免疫基因治疗研究院 |
一种基于cd10的嵌合抗原受体及其应用
|
CN107312098B
(zh)
*
|
2017-07-18 |
2020-06-12 |
深圳市免疫基因治疗研究院 |
一种基于cd22的嵌合抗原受体及其应用
|
CN107245107B
(zh)
*
|
2017-07-18 |
2020-02-07 |
深圳市免疫基因治疗研究院 |
一种基于cd20的嵌合抗原受体及其应用
|
CN111328280A
(zh)
|
2017-09-11 |
2020-06-23 |
阿托萨治疗学公司 |
制备和使用内昔芬的方法
|
CN107557336B
(zh)
*
|
2017-09-15 |
2020-02-14 |
山东兴瑞生物科技有限公司 |
一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用
|
CA3073848A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
CN109554349B
(zh)
*
|
2017-09-27 |
2022-06-24 |
亘喜生物科技(上海)有限公司 |
Pd-1基因表达沉默的工程化免疫细胞
|
CN109554348A
(zh)
*
|
2017-09-27 |
2019-04-02 |
亘喜生物科技(上海)有限公司 |
可诱导分泌抗cd47抗体的工程化免疫细胞
|
WO2019067677A1
(en)
|
2017-09-29 |
2019-04-04 |
Cell Design Labs, Inc. |
METHODS OF MANUFACTURING RECEPTORS OF ANTI-CD307E ANTI-BACTERIAL CHIMERIC ANTIGENS AND USES THEREFOR
|
CN109593721B
(zh)
*
|
2017-09-30 |
2022-11-01 |
亘喜生物科技(上海)有限公司 |
具有自杀基因开关的靶向人间皮素的工程化免疫细胞
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
JP2020537515A
(ja)
|
2017-10-03 |
2020-12-24 |
ジュノー セラピューティクス インコーポレイテッド |
Hpv特異的結合分子
|
JP2021502330A
(ja)
|
2017-10-20 |
2021-01-28 |
フレッド ハッチンソン キャンサー リサーチ センター |
Tigitおよび/またはcd112rを標的とするか、またはcd226過剰発現を含む、組成物および免疫治療の方法
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
CN111511370A
(zh)
|
2017-11-01 |
2020-08-07 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
|
KR20200116077A
(ko)
|
2017-11-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
|
CN111655270A
(zh)
*
|
2017-11-14 |
2020-09-11 |
纪念斯隆-凯特琳癌症中心 |
分泌il-36的免疫应答细胞及其用途
|
WO2019096136A1
(zh)
*
|
2017-11-14 |
2019-05-23 |
拜西欧斯(北京)生物技术有限公司 |
抗pd-1抗体及其制备方法和应用
|
US11649294B2
(en)
*
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
CN109971721B
(zh)
*
|
2017-12-28 |
2023-10-31 |
上海细胞治疗研究院 |
自表达cd47抗体的间皮素特异性car-t细胞及其用途
|
CN109971722B
(zh)
*
|
2017-12-28 |
2023-09-01 |
上海细胞治疗研究院 |
靶向cd19且高水平稳定表达cd40抗体的car-t细胞及其用途
|
CN109971725B
(zh)
*
|
2017-12-28 |
2024-02-02 |
上海细胞治疗研究院 |
抗体修饰的嵌合抗原受体修饰t细胞及其用途
|
CN109971716B
(zh)
*
|
2017-12-28 |
2023-08-01 |
上海细胞治疗研究院 |
自分泌cd47抗体的egfr特异性car-t细胞及其用途
|
CA3085606A1
(en)
*
|
2017-12-29 |
2019-07-04 |
Memorial Sloan-Kettering Cancer Center |
Enhanced chimeric antigen receptors and uses thereof
|
WO2019136305A1
(en)
*
|
2018-01-04 |
2019-07-11 |
Neumedicines Inc. |
Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
SG11202006416TA
(en)
*
|
2018-01-15 |
2020-08-28 |
Pfizer |
Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
|
EP3768700A1
(en)
|
2018-03-23 |
2021-01-27 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
EP3775214A2
(en)
|
2018-03-30 |
2021-02-17 |
University of Geneva |
Micro rna expression constructs and uses thereof
|
JP2021520202A
(ja)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現する細胞の作製方法および関連組成物
|
BR112020019313A2
(pt)
|
2018-04-05 |
2021-01-05 |
Juno Therapeutics Inc |
Receptores de células t e células modificadas que expressam os mesmos
|
JP2021521847A
(ja)
*
|
2018-04-26 |
2021-08-30 |
ベイラー カレッジ オブ メディスンBaylor College Of Medicine |
活性化された病原性t細胞およびnk細胞の選択的標的化のための自己/同種免疫防御受容体
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Bcmaキメラ抗原受容体及びその使用
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
TWI809130B
(zh)
|
2018-06-22 |
2023-07-21 |
美商凱特製藥公司 |
嵌合跨膜蛋白及其用途
|
CN112930186A
(zh)
*
|
2018-08-16 |
2021-06-08 |
纪念斯隆-凯特琳癌症中心 |
基于亮氨酸拉链的组合物和使用方法
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
US20210177832A1
(en)
|
2018-08-20 |
2021-06-17 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
US10780121B2
(en)
|
2018-08-29 |
2020-09-22 |
Shattuck Labs, Inc. |
FLT3L-based chimeric proteins
|
AU2019347873B2
(en)
*
|
2018-09-28 |
2024-08-22 |
Memorial Sloan-Kettering Cancer Center |
Immunoresponsive cells expressing dominant negative Fas and uses thereof
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
KR20210105344A
(ko)
*
|
2018-10-31 |
2021-08-26 |
휴머니건, 아이엔씨. |
암 치료용 물질 및 방법
|
WO2020095104A1
(en)
|
2018-11-05 |
2020-05-14 |
Ludwig Institute For Cancer Research Ltd. |
HUMANIZED AND VARIANT TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
|
US20210403546A1
(en)
|
2018-11-05 |
2021-12-30 |
Ludwig Institute For Cancer Research Ltd. |
Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
|
WO2020102240A1
(en)
*
|
2018-11-13 |
2020-05-22 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy for cancer
|
CA3119161A1
(en)
|
2018-11-13 |
2020-05-22 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
JP2022512994A
(ja)
*
|
2018-11-14 |
2022-02-07 |
メディシックス セラピューティクス ピーティーイー リミテッド |
Car-t細胞を生成する2遺伝子ベクターおよびその使用
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
MX2021007556A
(es)
|
2018-12-21 |
2021-09-10 |
Biontech Us Inc |
Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
WO2020226854A2
(en)
*
|
2019-04-12 |
2020-11-12 |
The Johns Hopkins University |
Tolerogenic artificial antigen-presenting cells
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
CN110343667A
(zh)
*
|
2019-07-17 |
2019-10-18 |
贝赛尔特(北京)生物技术有限公司 |
工程化的免疫细胞及其制备方法和应用
|
EP4010461A4
(en)
*
|
2019-08-05 |
2023-08-23 |
ImmunityBio, Inc. |
ARTIFICIAL TARGET CELLS FOR IN VITRO CAR CYTOTOXICITY AND ADCC VALIDATION
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
CN114651003A
(zh)
|
2019-09-10 |
2022-06-21 |
黑曜石疗法公司 |
用于可调调节的ca2-il15融合蛋白
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
AU2020380288B2
(en)
*
|
2019-11-04 |
2024-02-01 |
Inovio Pharmaceuticals, Inc. |
Combination therapy to treat brain cancer
|
CN112079934B
(zh)
*
|
2019-12-17 |
2021-01-29 |
合源生物科技(天津)有限公司 |
一种靶向cd19的嵌合抗原受体及其用途
|
CN116583607A
(zh)
|
2020-08-13 |
2023-08-11 |
耶鲁大学 |
用于工程改造和选择具有期望表型的car t细胞的组合物和方法
|
WO2022036495A1
(en)
|
2020-08-17 |
2022-02-24 |
Utc Therapeutics Inc. |
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
|
EP4203980A1
(en)
*
|
2020-08-28 |
2023-07-05 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Fusion protein enhancing cell therapy
|
CN111925990B
(zh)
*
|
2020-09-02 |
2022-08-26 |
北京立康生命科技有限公司 |
一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法
|
KR20230104222A
(ko)
|
2020-11-06 |
2023-07-07 |
노파르티스 아게 |
B 세포 악성종양 치료를 위한 항-cd19 작용제 및 b 세포 표적화제 병용 요법
|
EP4247850A1
(en)
|
2020-11-20 |
2023-09-27 |
Simcere Innovation, Inc. |
Armed dual car-t compositions and methods for cancer immunotherapy
|
MX2023010916A
(es)
|
2021-03-17 |
2023-12-14 |
Myeloid Therapeutics Inc |
Composiciones de proteinas de fusion quimericas modificadas por ingenieria y metodos de uso de las mismas.
|
WO2022220412A1
(ko)
*
|
2021-04-12 |
2022-10-20 |
메디젠 테라퓨틱스, 인코포레이티드 |
항원에 노출된 cd8 t 세포의 활성화 및 증식 방법 그리고 그에 의해 제조된 항암 활성이 강화된 cd8 t 세포 및 그의 용도
|
US20240207319A1
(en)
|
2021-05-06 |
2024-06-27 |
Ludwig Institute For Cancer Research Ltd |
Compositions and methods for immunotherapy
|
CA3216709A1
(en)
*
|
2021-05-13 |
2022-11-17 |
Katharine C. Hsu |
Nkg2c+ t cells and methods of use thereof
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2023243890A1
(ko)
*
|
2022-06-15 |
2023-12-21 |
주식회사 셀리드 |
자연 살해 t 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신
|
WO2023246840A1
(en)
*
|
2022-06-22 |
2023-12-28 |
Wuhan Houxian Biopharmaceutical Co. Ltd. |
Combination of il-12 and ox40l for cancer immunotherapy
|
WO2024064824A2
(en)
|
2022-09-21 |
2024-03-28 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
CN115850519B
(zh)
*
|
2022-12-12 |
2023-06-23 |
南京市浦口医院 |
一种靶向MAGE-A1且自分泌CD47 scFv的嵌合抗原受体及其应用
|
WO2024155821A1
(en)
|
2023-01-18 |
2024-07-25 |
Yale University |
Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
|